The scrutiny follows the July 22, 2026, disclosure of fiscal 2027 first-quarter results, where the company reported earnings per share of just $0.06. This performance was dragged down by a ₹2.4 billion provision linked to out-of-specification semaglutide batches. CEO Erez Israeli attributed the thin EBITDA margins to a combination of production losses, rejected inventory, and reduced sales incentives. Following the announcement, share prices slid $1.18 to close at $11.38. Investors who held stock during this period are now being encouraged to contact the firm to discuss potential class action participation.